The CEO says Wegovy’s sales were affected by the high competition competition outside the brand.

Novo Nord’s sales ((Non -governmental organizations-2.01 %)) Wegovy from Wegovy achieved great success due to the increasing competition from the brand, or the compound, according to the CEO of Danish Pharma Giant Giant Lars Fruergaard J Prietnsen.

Increased popularity Semaglutide – A copy of the active ingredient in Ozmpic and Wegovy was at the top of the company’s executives and shareholders at an annual meeting.

However, Jentsensen described that the company’s weight loss sales increased by 57 % last year.

“We are currently dealing with about 1.2 million obese patients in the United States, while 55 million people have insurance coverage for Wegovy,” said Jurgenin. “We continue to focus on scaling, display, commercial implementation and combating vehicle.”

Doubling It refers to the preparation for a drug that bears a brand otherwise by a pharmacy or a doctor to meet the specific needs of an individual patient. Medicines can also be aggravated under other circumstances, including when patented medications are in the event of a deficiency in the display. But with the increase in the production of Novo Nordisk and we no longer on the food and drug management (FDA) ListThe giant Pharma claims that most of the complex versions no longer justify them. The FDA (FDA) has also said it may begin to mention companies and healthcare providers that continue Starting May 22nd. Novo Nordisk Wegovy lists $ 1,349.02 per month, and drug scaling rules allowed vehicles to sell drugs at lower prices.

Juergenn admitted that “the large growth of the vehicle in the United States” affected Wigofi’s recipes in early 2025. HIMS & HERS started introducing Smaglutide complex Last May. The company’s total sales of 69 % last year to $ 1.5 billion.

One of the contributors asked about the period that the trend would take to reflect the direction, noting rumors that complex medications could represent up to 40 % of the obesity treatment market in the United States.

Jments -Juterensen has not provided a specific time schedule, but set the company’s multi -side strategy to combat competition from the two compounds.

Novo Nordsk says it publishes a mixture of legal procedures, communicating with doctors, and pricing incentives. The company filed a lawsuit against many complexes, and launched an advertising campaign to warn doctors and patients about the risks of not approved from FDA, and submitted only a new cash option Wegovy for $ 499 per month.